Paul Ruff
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Colorectal Cancer Surgical Treatments
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
Papers in
- Oncology 72
- Colorectal Cancer Treatments and Studies 23
- Viral-associated cancers and disorders 21
- Global Cancer Incidence and Screening 16
-
- Breast Cancer Treatment Studies 14
- Co-authors
- Eric Van Cutsem (9 shared papers)Gyorgy Bodoky (4 shared papers)Gunnar Folprecht (1 shared paper)Jae Kyung Roh (1 shared paper)Erika Hitre (1 shared paper)C.-H. Köhne (1 shared paper)Robert Lim (1 shared paper)Geert D’Haens (1 shared paper)
- Journals
- Annals of Oncology (8 papers)European Journal of Cancer (7 papers)The Lancet Oncology (6 papers)Breast Cancer Research and Treatment (5 papers)PLoS ONE (5 papers)
- Partner nations
- South AfricaUnited StatesUnited Kingdom
In The Last Decade
Paul Ruff
145 papers receiving 18.7k citations
Paul Ruff's Hit Papers
Peers
Comparison fields: 5 of 134
- Oncology 12.1k
- Otorhinolaryngology 1.3k
- Cancer Research 981
- Pulmonary and Respiratory Medicine 2.2k
- Hepatology 316
Countries citing papers authored by Paul Ruff
This map shows the geographic impact of Paul Ruff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Ruff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Ruff more than expected).
Fields of papers citing papers by Paul Ruff
This network shows the impact of papers produced by Paul Ruff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Ruff. The network helps show where Paul Ruff may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Ruff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 149 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Hit paper breakdown → | 2009 | 3202 |
| 2 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2712 |
| 3 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2497 |
| 4 | Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer Hit paper breakdown → | 2013 | 1875 |
| 5 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1500 |
| 6 | Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Hit paper breakdown → | 2012 | 1128 |
| 7 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1060 |
| 8 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 490 |
| 9 | 2014 | 476 | |
| 10 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 446 |
| 11 | 2014 | 387 | |
| 12 | 1999 | 227 | |
| 13 | 2007 | 218 | |
| 14 | 2013 | 182 | |
| 15 | 2000 | 142 | |
| 16 | 1990 | 140 | |
| 17 | 1991 | 131 | |
| 18 | 2008 | 129 | |
| 19 | 1997 | 117 | |
| 20 | 1987 | 92 |
About Paul Ruff
Paul Ruff is a scholar working on Oncology, Cancer Research, Infectious Diseases, Hematology and Emergency Medicine, having authored 149 papers that have together received 19.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (23 papers), Viral-associated cancers and disorders (21 papers), Global Cancer Incidence and Screening (16 papers), Breast Cancer Treatment Studies (14 papers), HIV/AIDS Research and Interventions (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), HIV-related health complications and treatments (5 papers) and Advances in Oncology and Radiotherapy (5 papers). The work is most often cited by research in Oncology (12.1k citations), Otorhinolaryngology (1.3k citations), Cancer Research (981 citations), Pulmonary and Respiratory Medicine (2.2k citations) and Hepatology (316 citations). Paul Ruff has collaborated with scholars based in South Africa, United States and United Kingdom. Frequent co-authors include Eric Van Cutsem, Gyorgy Bodoky, Gunnar Folprecht, Jae Kyung Roh, Erika Hitre, C.-H. Köhne, Robert Lim, Geert D’Haens, Jerzy Załuski and Christopher Stroh. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, The Lancet Oncology, Breast Cancer Research and Treatment and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.